


10098
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1647



Applicant: BECKER ET AL. Examiner: C. SAOUD
Serial No.: 10/018719 Group Art Unit: 1647
Filed: MARCH 21, 2002 Docket: 9077.1USWO
Confirmation No.: 8053 Notice of Allow. --
Date:
Due Date: OCTOBER 30, 2003
Title: USE OF GROWTH HORMONE (HGH) FOR THE TREATMENT OF SEXUAL
FUNCTIONAL DISTURBANCES

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: , Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 10-13-03

By: Kay Fahlend
Name: Kay Fahlend

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

23552
PATENT TRADEMARK OFFICE

Sir:

We are transmitting herewith the attached:

- Transmittal Sheet in duplicate containing Certificate of Mailing
- Response to Restriction Requirement
- Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C.
P.O. Box 2903, Minneapolis, MN 55402-0903
612.332.5300

By: Ronald A. Daignault
Name: Ronald A. Daignault
Reg. No.: 25,968
RADAignault:kf

CUSTOMER NUMBER 23552

S/N 10/018719



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: BECKER ET AL. Examiner: C. SAoud
Serial No.: 10/018719 Group Art Unit: 1647
Filed: MARCH 21, 2002 Docket No.: 9077.1USWO
Title: USE OF GROWTH HORMONE (HGH) FOR THE TREATMENT OF
SEXUAL FUNCTIONAL DISTURBANCES

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited in the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on
10-13-03.

By: Kay Fahlund
Name: Kay Fahlund

RESPONSE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the restriction requirement of September 3, 2003, Applicants elect Group I, claims 12-15 drawn to a method of treating sexual function disorders by administration of a growth hormone or combinations with a growth hormone. This election is made with traverse.

As the Examiner recognizes, the method claims and all of the pending claims are the same. The variety in active ingredient is not to the extent that requires extensive further examination. In fact these very ingredients are part of the dependent claims in combination therapy with a growth hormone.

Should the restriction requirement be made final, Applicants reserve the right to file divisional applications on the non-elected subject matter.

Prosecution on the merits is earnestly solicited.

Respectfully submitted,

10/13/03
Date



Ronald A. Daignault
Reg. No. 25,968
Merchant & Gould P.C.
P. O. Box 2903
Minneapolis, MN 55402-0903
(612) 371-5381

CUSTOMER NUMBER 23552

RAD:kf